ClinicalTrials.gg
Status unknownNCT04948788Updated Sep 28, 2021

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

A Phase 2 interventional study of SHR1459 ;YY-20394 and SHR1459 ;YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-28.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.

02

Conditions studied

  • Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Browse trials for

03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of B-cell NHL such as DLBCL, FL and MCL
  2. Patients received at least 2
  3. Previously received anti- CD20 treatment
  4. Patients in stage II should also be unsuitable or unwilling to receive hematopoietic stem cell transplantation
  5. Patients must have an acceptable organ function

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with PI3K inhibitors or BTK inhibitors
  2. Unresolved toxicity of grade > 1 from prior anti-lymphoma therapy
  3. Chemotherapy or other therapy within 28 days (or 5 times the half-life time, whichever is shorter) before starting cycle 1
  4. Significant concurrent medical disease or condition which according to the investigators' judgement
  5. Active , C or infection
  6. Infection requiring treatment 2 weeks prior to the first dosing
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    SHR1459 + YY-20394 (Stage 1)

    Drug: SHR1459 ;YY-20394

  • Experimental
    SHR1459 + YY-20394 (Stage 2)

    Drug: SHR1459 ;YY-20394

  • Experimental
    GemOx (Stage 2)

    Drug: Gemcitabine-Oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Stage 1: MTD (Maximum tolerated dose)or RP2D(Recommended Phase II Dose) of SHR1459 and YY-20394;

    Time frame: Minimum observation period is 28 days for the maximum dose cohort

  2. Stage 2: Overall response rate (ORR)

    Time frame: 8 weeks after last patient first visit (LPFV)

Secondary outcomes

  1. Incidence of Adverse Events

    Time frame: At every treatment and follow up visit until disease progression. Expected to be for up to 6 months

07

Study locations

1 of 1 sites recruiting
  • Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
    Shanghai, Shanghai 200025, China
    Recruiting
    • Weili Zhao · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2021; primary completion for Apr 2023, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 2, 2021
StartEst.
Oct 2021
Primary completionEst.
Apr 2023
CompletionEst.
Oct 2023
Last update
Sep 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04948788
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Oct 2021 (estimated)
Primary completion
Apr 2023 (estimated)
Completion
Oct 2023 (estimated)
Last update
Sep 28, 2021

Study contacts

Weiwei Wang
Contact
weiwei.wang@hengrui.com
021-61053363

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Edralbrutinib · Gemcitabine-oxaliplatin regimen

Start the discussion